Wedbush Brokers Reduce Earnings Estimates for Generation Bio

Generation Bio Co. (NASDAQ:GBIO) – Equities researchers at Wedbush reduced their Q3 2025 earnings per share estimates for Generation Bio in a research note issued on Wednesday, August 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($3.15) per share for the quarter, down from their prior forecast of ($2.94). Wedbush currently has a “Neutral” rating and a $7.00 target price on the stock. The consensus estimate for Generation Bio’s current full-year earnings is ($1.75) per share. Wedbush also issued estimates for Generation Bio’s Q4 2025 earnings at ($1.08) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.48) EPS.

Several other research firms have also weighed in on GBIO. Wall Street Zen lowered Generation Bio from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Generation Bio in a research report on Wednesday.

Generation Bio Stock Down 5.6%

Shares of Generation Bio stock opened at $6.29 on Friday. The firm has a market capitalization of $42.39 million, a PE ratio of -0.58 and a beta of 2.67. Generation Bio has a 12-month low of $3.00 and a 12-month high of $29.40. The stock’s fifty day moving average is $4.15 and its 200-day moving average is $4.61.

Generation Bio (NASDAQ:GBIO) last announced its earnings results on Tuesday, August 12th. The company reported ($3.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.80) by ($0.32). The company had revenue of $0.77 million for the quarter, compared to analyst estimates of $2.51 million. Generation Bio had a negative return on equity of 91.07% and a negative net margin of 341.12%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Militia Capital Partners LP purchased a new position in Generation Bio in the second quarter valued at about $174,000. Marshall Wace LLP purchased a new position in Generation Bio in the second quarter valued at about $37,000. Y Intercept Hong Kong Ltd purchased a new position in Generation Bio in the second quarter valued at about $47,000. Acadian Asset Management LLC grew its stake in Generation Bio by 54.3% in the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock valued at $468,000 after purchasing an additional 407,843 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in Generation Bio in the first quarter valued at about $36,000. 95.22% of the stock is owned by institutional investors and hedge funds.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.